WC
TSHA icon

Wexford Capital’s Taysha Gene Therapies TSHA Stock Holding History

Wexford Capital’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Hold
160,654
– – 0.14% 59
2026
Q1 		$718K Sell
160,654
-20,199
-11% -$93.9K 0.1% 68
2025
Q4 		$995K Buy
180,853
+177,353
+5,067% +$861K 0.19% 78
2025
Q3 		$11.4K Buy
+3,500
New +$9.91K ﹤0.01% 397

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wexford Capital's TSHA Position: Q2 2026 in Review

Wexford Capital held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 160,654 shares worth $1.09M. The position accounts for 0.14% of the portfolio, ranked #59.

Wexford Capital first reported a position in TSHA in Q3 2025 and has held it in 4 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Wexford Capital held 160,654 shares of Taysha Gene Therapies worth $1.09M as of Q2 2026.
  • Wexford Capital left its Taysha Gene Therapies share count unchanged in Q2 2026.
  • Taysha Gene Therapies made up 0.14% of Wexford Capital's portfolio in Q2 2026, its #59 holding.
  • Wexford Capital first reported a position in Taysha Gene Therapies in Q3 2025 and has held it in 4 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Wexford Capital's 13F filing for Q2 2026, filed 14 Aug 2026.